These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37906406)

  • 1. Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen.
    Stroffolini G; Lazzaro A; Barco A; Pirriatore V; Vai D; Giaccone C; Nigra M; Atzori C; Trunfio M; Bonora S; Di Perri G G; Calcagno A
    J Neuroimmune Pharmacol; 2023 Dec; 18(4):551-562. PubMed ID: 37906406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders.
    Barco A; Orlando S; Stroffolini G; Pirriatore V; Lazzaro A; Vai D; Guastamacchia G; Noce G; Atzori C; Trunfio M; Bonora S; Di Perri G; Calcagno A
    J Neurovirol; 2022 Apr; 28(2):226-235. PubMed ID: 35044644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
    Lazzaro A; Vai D; Barco A; Stroffolini G; Pirriatore V; Guastamacchia G; Nigra M; Ghisetti V; Tettoni MC; Noce G; Giaccone C; Trunfio M; Trentalange A; Bonora S; Di Perri G; Calcagno A
    J Acquir Immune Defic Syndr; 2024 Oct; 97(2):180-191. PubMed ID: 39250652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
    Barber TJ; Imaz A; Boffito M; Niubó J; Pozniak A; Fortuny R; Alonso J; Davies N; Mandalia S; Podzamczer D; Gazzard B
    J Neurovirol; 2018 Feb; 24(1):98-105. PubMed ID: 29280108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.
    Motta I; Allice T; Romito A; Ferrara M; Ecclesia S; Imperiale D; Ghisetti V; Di Perri G; Bonora S; Calcagno A
    Antivir Ther; 2017; 22(6):539-543. PubMed ID: 28198350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV.
    Trunfio M; Mighetto L; Napoli L; Atzori C; Nigra M; Guastamacchia G; Bonora S; Di Perri G; Calcagno A
    J Neuroimmune Pharmacol; 2023 Jun; 18(1-2):169-182. PubMed ID: 37166552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
    Orkin C; Molina JM; Negredo E; Arribas JR; Gathe J; Eron JJ; Van Landuyt E; Lathouwers E; Hufkens V; Petrovic R; Vanveggel S; Opsomer M;
    Lancet HIV; 2018 Jan; 5(1):e23-e34. PubMed ID: 28993180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals.
    Ceccarelli G; Brenchley JM; Cavallari EN; Scheri GC; Fratino M; Pinacchio C; Schietroma I; Fard SN; Scagnolari C; Mezzaroma I; Vullo V; d'Ettorre G
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29160817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.
    Ulfhammer G; Edén A; Mellgren Å; Fuchs D; Zetterberg H; Hagberg L; Nilsson S; Yilmaz A; Gisslén M
    AIDS; 2018 Sep; 32(15):2171-2178. PubMed ID: 30005007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.
    Guha D; Mukerji SS; Chettimada S; Misra V; Lorenz DR; Morgello S; Gabuzda D
    AIDS; 2019 Mar; 33(4):615-625. PubMed ID: 30557159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
    Podzamczer D; Imaz A; Lopez-Lirola A; Knobel H; Masiá M; Fanciulli C; Hernández C; Lagarde M; Gutierrez A; Curran A; Morano L; Montero-Alonso M; Troya J; Rigo R; Casadellà M; Navarro-Alcaraz A; Ardila F; Parera M; Bernal E; Echeverria P; Estrada V; Hidalgo-Tenorio C; Macias J; Prieto P; Portilla J; Valencia E; Vivancos MJ; Rivero A
    J Antimicrob Chemother; 2023 Nov; 78(11):2696-2701. PubMed ID: 37725999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
    Rashbaum B; Spinner CD; McDonald C; Mussini C; Jezorwski J; Luo D; Van Landuyt E; Brown K; Wong EY
    HIV Res Clin Pract; 2019 Feb; 20(1):24-33. PubMed ID: 31303147
    [No Abstract]   [Full Text] [Related]  

  • 15. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
    Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Viral Persistence and Atherosclerosis in Adults With Treated HIV Infection.
    McLaughlin MM; Ma Y; Scherzer R; Rahalkar S; Martin JN; Mills C; Milush J; Deeks SG; Hsue PY
    JAMA Netw Open; 2020 Oct; 3(10):e2018099. PubMed ID: 33119103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.
    Edén A; Marcotte TD; Heaton RK; Nilsson S; Zetterberg H; Fuchs D; Franklin D; Price RW; Grant I; Letendre SL; Gisslén M
    PLoS One; 2016; 11(6):e0157160. PubMed ID: 27295036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.
    Jespersen S; Pedersen KK; Anesten B; Zetterberg H; Fuchs D; Gisslén M; Hagberg L; Trøseid M; Nielsen SD
    BMC Infect Dis; 2016 Apr; 16():176. PubMed ID: 27103116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study.
    Filippidis P; Damas J; Viala B; Assal F; Nawej Tshikung O; Tarr P; Derfuss T; Oberholzer M; Jelcic I; Hundsberger T; Sacco L; Cavassini M; Du Pasquier R; Darling KEA;
    J Acquir Immune Defic Syndr; 2023 Jul; 93(3):219-228. PubMed ID: 36927958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
    Kelesidis T; Tran TTT; Brown TT; Moser C; Ribaudo HJ; Dube MP; Yang OO; McComsey GA; Stein JH; Currier JS
    Antivir Ther; 2017; 22(2):113-126. PubMed ID: 27661466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.